Vancouver, British Columbia, August 18, 2023 – Treatment.com International Inc. (the “Company” or “Treatment”) (CSE: TRUE; OTC: TREIF; FFA: 939) is pleased to announce it has arranged a private placement of $1,000,000 issuable for 10,000,000 shares (the “Private Placement”). Additionally, the Company will settle up to $1,800,000 of Company liabilities at a price of $0.10 per share for up to 18,000,000 shares (the “Debt Settlement”). The Private Placement and Debt Settlement are being completed pursuant to a price reservation filed July 25, 2023. Closing of the financing is subject to the Canadian Securities Exchange approval and shareholder approval pursuant to the policies of the Canadian Securities Exchange. The Private Placement is being conducted pursuant to National Instrument 45-106, Part 5A, Listed Issuer Finance Exemption. There is an offering document related to the Private Placement that can be accessed under the Company’s profile at www.sedarplus.ca and at and at https://treatment.com/. Prospective investors should read this offering document before making an investment decision.
The net proceeds of the Private Placement are expected to be used for general working capital purposes. No Finder’s fees are payable in connection with the Private Placement.
The securities issued pursuant to the Private Placement have not, nor will they be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons in the absence of U.S. registration or an applicable exemption from the U.S. registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or in any other jurisdiction in which such offer, solicitation or sale would be unlawful.
Treatment.com is a disruptive artificial intelligence platform providing healthcare organizations and medical professionals with access to intelligent, personalized, diagnostic and treatment resources. Based on a neural network of high quality validated medical knowledge covering over 1,000 diagnoses and tens of thousands of symptoms, findings, laboratory tests, and risk factors, the company provides access to the Global Library of Medicine using sophisticated interfaces that speed the integration of diagnostic and treatment capabilities into new or existing software.
For more investor information on Treatment.com please visit https://treatment.com/investors/.
Release issued by: Kevin Peterson, Interim CEO
Main Line: +1 (612) 788-8900
Toll Free USA/Canada: +1 (888) 788-8955
This news release contains forward-looking statements relating to the future operations of Treatment and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the Private Placement, the use of proceeds of the Private Placement, and future plans and objectives of Treatment, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from Treatment’s expectations include other risks detailed from time to time in the filings made by Treatment with securities regulators.
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of Treatment. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and Treatment will only update or revise publicly the included forward-looking statements as expressly required by Canadian securities law.
The Canadian Stock Exchange, nor its regulation service provider, accept responsibility for the adequacy or accuracy of this news release.